Page 84 - 《中国药房》2025年23期
P. 84

·药物与临床·


          依洛尤单抗联合阿托伐他汀对急性 ST 段抬高型心肌梗死患者
          PCI术后疗效及冠状动脉微循环的影响                                          Δ



          朱 芸 ,韩克丽 ,李 杰 ,穆 清 ,张 琮 (1.南阳医学高等专科学校第一附属医院特需病区,河南 南阳
                           2
                 1*
                                   3
                                                   1 #
                                           4
          473000;2.南阳市中心医院心血管内科二病区,河南 南阳  473000;3.南阳医学高等专科学校第一附属医院心
          血管内科四病区,河南 南阳 473000;4.南阳医学高等专科学校第一附属医院心血管内科三病区,河南 南阳
          473000)
          中图分类号  R972+.6;R969.4      文献标志码  A      文章编号  1001-0408(2025)23-2958-05
          DOI  10.6039/j.issn.1001-0408.2025.23.13

          摘   要  目的  探讨依洛尤单抗联合阿托伐他汀对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)术后疗
          效及冠状动脉微循环的影响。方法  回顾性纳入2022年1月-2024年12月在南阳医学高等专科学校第一附属医院被诊断为急性
          STEMI并进行PCI术的住院患者194例,根据治疗方案的不同分为对照组(100例)和联合治疗组(94例)。对照组患者口服阿托伐
          他汀钙片20 mg,每天1次;联合治疗组患者在对照组基础上,先于PCI术后24 h内注射依洛尤单抗注射液140 mg,然后维持每2周
          注射1次;两组患者连续治疗至少30 d。比较两组患者治疗前及治疗30 d后的血脂指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂
          蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇]、炎症指标[C反应蛋白(CRP)和白细胞介素6(IL-6)]、血管内皮功能及微循环指标
          [纤维蛋白原、踝臂指数(ABI)、一氧化氮(NO)]、心功能指标[左室射血分数(LVEF)、左室舒张末期内径、左室收缩末期内径],以及
          治疗期间不良反应发生情况。结果  治疗前,两组患者的血脂、炎症、血管内皮功能及微循环、心功能指标比较,差异均无统计学意
          义(P>0.05);治疗30 d后,两组患者的TC、TG、LDL-C、CRP、IL-6、纤维蛋白原水平均较同组治疗前显著降低,NO水平、LVEF和
          联合治疗组患者的ABI均较同组治疗前显著升高,且联合治疗组患者的TC、LDL-C、CRP、IL-6、纤维蛋白原、NO水平的改善程度
          均较同期对照组显著(P<0.05)。两组患者肝功能损害、消化道不良反应的发生率及总不良反应发生率比较,差异均无统计学意
          义(P>0.05)。结论  与单用阿托伐他汀相比,依洛尤单抗联合阿托伐他汀治疗能更有效地降低急性STEMI患者PCI术后的血脂
          水平,改善炎症状态、血管内皮功能和冠状动脉微循环,且其安全性与单用阿托伐他汀相当。
          关键词  依洛尤单抗;阿托伐他汀;急性ST段抬高型心肌梗死;经皮冠状动脉介入治疗;冠状动脉微循环;疗效;安全性

          The  effects  of  evolocumab  combined  with  atorvastatin  on  post-PCI  efficacy  and  coronary  microcirculation
          in patients with acute ST-segment elevation myocardial infarction
          ZHU Yun ,HAN Keli ,LI Jie ,MU Qing ,ZHANG Cong(1. Special Needs Ward, the First Affiliated Hospital of
                                                            1
                             2
                                    3
                   1
                                              4
          Nanyang  Medical  College,  Henan  Nanyang  473000,  China;2.  Cardiovascular  Medicine  Ward  2,  Nanyang
          Central  Hospital,  Henan  Nanyang  473000,  China;3.  Cardiovascular  Medicine  Ward  4,  the  First  Affiliated
          Hospital of Nanyang Medical College, Henan Nanyang 473000, China;4. Cardiovascular Medicine Ward 3, the
          First Affiliated Hospital of Nanyang Medical College, Henan Nanyang 473000, China)
          ABSTRACT    OBJECTIVE  To  investigate  the  effects  of  evolocumab  combined  with  atorvastatin  on  post-percutaneous  coronary
          intervention (PCI)  efficacy  and  coronary  microcirculation  in  patients  with  acute  ST-segment  elevation  myocardial  infarction
         (STEMI). METHODS This retrospective cohort study included 194 hospitalized patients with acute STEMI who underwent PCI in
          the First Affiliated Hospital of Nanyang Medical College from Jan. 2022 to Dec. 2024. The patients were divided into control group
         (100  cases)  and  combination  therapy  group (94  cases)  according  to  the  different  therapy  plans.  The  control  group  was  given
          Atorvastatin  calcium  tablets  orally,  at  a  dose  of  20  mg,  once  a  day.  On  the  basis  of  the  control  group,  the  combination  therapy
          group  received  an  initial  injection  of  Evolocumab  injection  140  mg  within  24  hours  after  PCI,  followed  by  subsequent  injections
          every  2  weeks.  Both  groups  received  continuous  treatment  for  at  least  30  days.  Blood  lipid  indicators  [total  cholesterol (TC),
          triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol], inflammation indicators
                                                              [C-reactive  protein (CRP)  and  interleukin-6 (IL-6)],  vascular
              Δ 基金项目 河南省医学科技攻关计划项目(No.LHGJ20230971)
             *第一作者 副主任护师。研究方向 :心内科护理。E-mail:                  endothelial   function   and   microcirculation   indicators
                                                              [fibrinogen,  ankle-brachial  index  (ABI)  and  nitric  oxide
          txbfzhuyun@163.com
              #  通信作者 主任医师。研究方向:冠心病及其介入治疗。                   (NO)],  cardiac  function  indicators  [left  ventricular  ejection
          E-mail:zhangcong1950@163.com                        fraction (LVEF),  left  ventricular  end-diastolic  diameter  and


          · 2958 ·    China Pharmacy  2025 Vol. 36  No. 23                            中国药房  2025年第36卷第23期
   79   80   81   82   83   84   85   86   87   88   89